USFDA29 May 2026, 09:11 pm
Jubilant Pharmova: USFDA Issues Warning Letter for Canada Facility
AI Summary
Jubilant Pharmova's subsidiary, Jubilant HollisterStier General Partnership (JHSGP), received a Warning Letter from the USFDA following an inspection at its Kirkland, Canada facility in October-November 2025. The review concluded the inspection report. JHSGP has initiated corrective actions, and Jubilant Pharmova emphasizes that current operations proceed under enhanced controls while remediation is underway.
Key Highlights
- USFDA issued a Warning Letter after inspecting Jubilant HollisterStier's Canada facility.
- The inspection took place during October 20 to November 3, 2025.
- JHSGP has already started corrective and preventive actions.
- Current operations at the facility are proceeding under enhanced controls.
- JHSGP is jointly owned by subsidiaries of Jubilant Pharma Limited.
Price Impact
More from JUBLPHARMA